Skip to content

Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease

Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease: A Multicenter Prospective Cohort Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04266600
Enrollment
29
Registered
2020-02-12
Start date
2019-09-27
Completion date
2024-09-27
Last updated
2021-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Crohn's Ileocolitis, Recurrence

Brief summary

The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's disease. It is a prospective study that has been designed to perform extended mesenteric excision on patients undergoing their first ileocolic resection for Crohn's disease. Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection. (limited mesenteric resection).

Detailed description

The current standard of care for ileocolic Crohn's disease (CD) is a limited mesenteric resection. There is growing, but still limited, evidence that extended mesenteric excision during ileocolic resection is beneficial in decreasing disease recurrence. We propose a prospective multicenter cohort study to better understand the role of extended mesenteric excision in ileocolic CD and how it affects disease recurrence. The primary outcome of this study will be the rate of endoscopic recurrence at 6 months in patients undergoing first-time resection for ileocolic CD. Secondary outcomes will include endoscopic recurrence at 18 months and rates of recurrence requiring surgery by 2 years. These outcomes will be compared to historical controls (limited mesenteric resection). Our hypothesis is that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection. As seen in previous studies, advanced mesenteric and mucosal disease predicts increased surgical recurrence.

Interventions

PROCEDUREExtensive mesentery resection

Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis

Sponsors

Montreal General Hospital
CollaboratorOTHER
Jewish General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

adults \>18 years old diagnosis of CD limited to the distal ileum/ileocolic region no previous ileocolic resection all forms of CD presentation will be included - stricturing, fistulizing, perforating etc.

Exclusion criteria

previous ileocolic resection other sites of CD intraabdominal sepsis

Design outcomes

Primary

MeasureTime frameDescription
Endoscopic recurrence at 6 months6 monthsEndoscopic recurrence after extended mesenteric ileocolic resection

Secondary

MeasureTime frameDescription
Endoscopic recurrence at 18 months18 monthsEndoscopic recurrence will be evaluated by the endoscopist and will be evaluated according to the Rutgeert's score
Rates of recurrence requiring surgery by 2 years24 monthsSurgical recurrence after extended mesenteric ileocolic resection
Post-operative complications30 daysPost-operative complications including: wound infections, anastomotic leak, intra-abdominal abscess, venous-thromboembolic complications, and primary ileus within 30 days of the first resection.

Countries

Canada

Contacts

Primary ContactMarylise Boutros, MD
marylise.boutros@mcgill.ca514-340-8222
Backup ContactSender Liberman, MD
sender.liberman@mcgill.ca5149348486

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026